Dexcom [DXCM] vs Edwards Lifesciences [EW] Detailed Stock Comparison
Dexcom
NASDAQ
Loading...
Edwards Lifesciences
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Dexcom wins in 5 metrics, Edwards Lifesciences wins in 14 metrics, with 0 ties. Edwards Lifesciences appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Dexcom | Edwards Lifesciences | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 47.39 | 31.40 | Edwards Lifesciences |
| Price-to-Book Ratio | 10.18 | 4.25 | Edwards Lifesciences |
| Debt-to-Equity Ratio | 100.24 | 6.62 | Edwards Lifesciences |
| PEG Ratio | 1.71 | -4.79 | Edwards Lifesciences |
| EV/EBITDA | 27.85 | 24.33 | Edwards Lifesciences |
| Profit Margin (TTM) | 13.29% | 72.96% | Edwards Lifesciences |
| Operating Margin (TTM) | 18.37% | 28.12% | Edwards Lifesciences |
| EBITDA Margin (TTM) | 18.37% | 28.12% | Edwards Lifesciences |
| Return on Equity | 22.83% | 15.53% | Dexcom |
| Return on Assets (TTM) | 6.08% | 8.42% | Edwards Lifesciences |
| Free Cash Flow (TTM) | $630.70M | $259.90M | Dexcom |
| 1-Year Return | -2.45% | 17.04% | Edwards Lifesciences |
| Price-to-Sales Ratio (TTM) | 6.15 | 7.88 | Dexcom |
| Enterprise Value | $25.71B | $42.36B | Edwards Lifesciences |
| EV/Revenue Ratio | 5.98 | 7.45 | Dexcom |
| Gross Profit Margin (TTM) | 59.53% | 77.52% | Edwards Lifesciences |
| Revenue per Share (TTM) | $11 | $10 | Dexcom |
| Earnings per Share (Diluted) | $1.41 | $2.43 | Edwards Lifesciences |
| Beta (Stock Volatility) | 1.49 | 1.07 | Edwards Lifesciences |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Dexcom vs Edwards Lifesciences Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Dexcom | 0.54% | -2.72% | -10.58% | -20.51% | -2.49% | -15.36% |
| Edwards Lifesciences | 0.45% | 1.83% | -6.26% | -0.48% | 6.38% | 5.59% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Dexcom | -2.45% | -34.95% | -31.15% | 242.65% | 1,848.39% | 2,085.53% |
| Edwards Lifesciences | 17.04% | -9.00% | -8.64% | 210.32% | 575.93% | 2,035.10% |
News Based Sentiment: Dexcom vs Edwards Lifesciences
Dexcom
News based Sentiment: MIXED
Dexcom experienced a month of conflicting signals. While Q2 earnings beat expectations and revenue grew, concerns about regulatory delays, product safety allegations, and analyst downgrades created significant volatility and uncertainty, making it a mixed bag for investors.
Edwards Lifesciences
News based Sentiment: MIXED
October brought a mix of positive and negative developments for Edwards Lifesciences. While the stock received an upgrade and the healthcare sector outlook improved, earnings are expected to decline year-over-year. This creates a balanced investment narrative requiring close monitoring of upcoming earnings.
Performance & Financial Health Analysis: Dexcom vs Edwards Lifesciences
| Metric | DXCM | EW |
|---|---|---|
| Market Information | ||
| Market Cap | $26.16B | $45.70B |
| Market Cap Category | Large cap | Large cap |
| 10 Day Avg. Volume | 8,183,612 | 4,916,428 |
| 90 Day Avg. Volume | 5,586,657 | 4,313,783 |
| Last Close | $66.44 | $76.65 |
| 52 Week Range | $57.52 - $93.25 | $64.01 - $83.00 |
| % from 52W High | -28.75% | -7.65% |
| All-Time High | $164.86 (Nov 15, 2021) | $131.73 (Dec 27, 2021) |
| % from All-Time High | -59.70% | -41.81% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.15% | 0.12% |
| Quarterly Earnings Growth | 0.25% | -0.09% |
| Financial Health | ||
| Profit Margin (TTM) | 0.13% | 0.73% |
| Operating Margin (TTM) | 0.18% | 0.28% |
| Return on Equity (TTM) | 0.23% | 0.16% |
| Debt to Equity (MRQ) | 100.24 | 6.62 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $6.56 | $17.94 |
| Cash per Share (MRQ) | $7.47 | $6.92 |
| Operating Cash Flow (TTM) | $987.70M | $794.90M |
| Levered Free Cash Flow (TTM) | $425.12M | $1.26B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Dexcom vs Edwards Lifesciences
| Metric | DXCM | EW |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 47.39 | 31.40 |
| Forward P/E | 32.91 | 31.15 |
| PEG Ratio | 1.71 | -4.79 |
| Price to Sales (TTM) | 6.15 | 7.88 |
| Price to Book (MRQ) | 10.18 | 4.25 |
| Market Capitalization | ||
| Market Capitalization | $26.16B | $45.70B |
| Enterprise Value | $25.71B | $42.36B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 5.98 | 7.45 |
| Enterprise to EBITDA | 27.85 | 24.33 |
| Risk & Other Metrics | ||
| Beta | 1.49 | 1.07 |
| Book Value per Share (MRQ) | $6.56 | $17.94 |
Financial Statements Comparison: Dexcom vs Edwards Lifesciences
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | DXCM | EW |
|---|---|---|
| Revenue/Sales | $1.04B | $1.41B |
| Cost of Goods Sold | $447.00M | $301.60M |
| Gross Profit | $589.00M | $1.11B |
| Research & Development | $145.20M | $254.60M |
| Operating Income (EBIT) | $133.70M | $409.90M |
| EBITDA | $219.00M | $461.60M |
| Pre-Tax Income | $154.30M | $433.90M |
| Income Tax | $48.90M | $70.30M |
| Net Income (Profit) | $105.40M | $356.40M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | DXCM | EW |
|---|---|---|
| Cash & Equivalents | $904.90M | $3.14B |
| Total Current Assets | $4.55B | $6.21B |
| Total Current Liabilities | $3.04B | $1.39B |
| Long-Term Debt | $1.36B | $675.70M |
| Total Shareholders Equity | $2.27B | $10.19B |
| Retained Earnings | $1.70B | $13.53B |
| Property, Plant & Equipment | $59.10M | $1.80B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | DXCM | EW |
|---|---|---|
| Operating Cash Flow | $167.90M | $294.00M |
| Capital Expenditures | $-87.00M | N/A |
| Free Cash Flow | $96.80M | $224.40M |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | $-258.60M |
Short Interest & Institutional Ownership Analysis
| Metric | DXCM | EW |
|---|---|---|
| Shares Short | 13.14M | 7.26M |
| Short Ratio | 3.18 | 1.86 |
| Short % of Float | 0.04% | 0.01% |
| Average Daily Volume (10 Day) | 8,183,612 | 4,916,428 |
| Average Daily Volume (90 Day) | 5,586,657 | 4,313,783 |
| Shares Outstanding | 390.70M | 588.60M |
| Float Shares | 389.52M | 581.11M |
| % Held by Insiders | 0.00% | 0.01% |
| % Held by Institutions | 0.97% | 0.88% |
Dividend Analysis & Yield Comparison: Dexcom vs Edwards Lifesciences
| Metric | DXCM | EW |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |